Two inositol phospholipid-specific phospholipase C (PLC) isozymes (PLC-I and -II) have been purified from bovine brain. When PLC-I or PLC-il was microinjected (100-700 ,ug/ml) into quiescent NIH 3T3 cells, a time-and dose-dependent induction of DNA synthesis occurred, as demonstrated by [3H]thymidine incorporation into nuclear DNA. In addition, =8 hr after PLC injection, NIH 3T3 fibroblasts appeared spindle-shaped, refractile, and highly vacuolated, displaying a morphology similar to transformed cells. The morphologic transformation was apparent for 26-30 hr after which the injected cells reverted back to a normal phenotype.
(100-700 ,ug/ml) into quiescent NIH 3T3 cells, a time-and dose-dependent induction of DNA synthesis occurred, as demonstrated by [3H]thymidine incorporation into nuclear DNA. In addition, =8 hr after PLC injection, NIH 3T3 fibroblasts appeared spindle-shaped, refractile, and highly vacuolated, displaying a morphology similar to transformed cells. The morphologic transformation was apparent for 26-30 hr after which the injected cells reverted back to a normal phenotype.
Microinjected PLC at a high concentration (1 mg/ml) was cytotoxic, dissolving the cytoplasmic membrane and leaving behind cellular ghosts. PLC is a key regulatory enzyme involved in cellular membrane signal transduction. Introduction of exogenous PLC into NIH 3T3 cells by microinjection induced a growth and oncogenic potential, as demonstrated by the ability of microinjected PLC (-"10,000 molecules per cell) to override the cellular Go block, inducing DNA synthesis and morphologic transformation of growth-arrested fibroblast cells.
Inositol phospholipid-specific phospholipase C (PLC) (1, 2) is central to the mechanism of membrane signal transduction because it hydrolyses phosphoinositol bisphosphate, generating two second messenger molecules, inositol trisphosphate and diacylglycerol, in response to several receptorbinding polypeptide hormones (3, 4) . Diacylglycerol, an integral component of the cytoplasmic membrane, allosterically activates protein kinase C (5, 6), whereas inositol trisphosphate induces the release of Ca2+ from intracellular membrane stores (7) . The cellular response to an increase in intracellular Ca2+ and to activation of protein kinase C is synergistic when both pathways are operating simultaneously (8) . The molecular events that regulate transmembrane signaling and elicit the production of diacylglycerol and inositol trisphosphate have not been defined clearly, but several studies have implicated guanine nucleotide-binding regulatory proteins (G proteins) (7, 9) . Models of Gprotein-regulated signal transduction (10) propose mechanisms in which receptor-mediated hydrolysis of phosphoinositol bisphosphate is coupled through G-protein-dependent activation of PLC (11, 12) .
Several research groups have cloned and sequenced isozymes of PLC (13, 14) . They reported that PLC-II contains a region that has significant sequence homology to several oncogenes of the nonreceptor tyrosine kinase class, such as src (15) , yes, fgr, abl, fps, and fes (16) , and a recently identified oncogene crk (17) . The region of homology is located in the noncatalytic domain that is not essential for tyrosine kinase activity but may be involved in interactions of these isozymes with cellular components that modulate kinase function. PLC and cytoplasmic tyrosine kinases may be regulated by common cellular components, such as G proteins.
Microinjection by using a glass capillary tube is an established method of introducing macromolecules into living mammalian cells to study their intracellular biological effects. Injection of the ras gene product p21 demonstrated that this purified oncoprotein was sufficient to override the Go block of serum-deprived mouse fibroblast cells, inducing the S phase of the cell cycle. Furthermore, microinjection of ras p21 protein into normal mouse fibroblasts induced a temporary morphologic transformation (18, 19) . The c-myc protein, after microinjection into the nuclei of quiescent Swiss 3T3 cells, cooperated with platelet-derived growth factor to stimulate cellular DNA synthesis, suggesting that c-myc may function as an intracellular competence factor (20) . Microinjection has proven to be a powerful tool for the study of oncogenes and membrane signal transduction hierarchy (18) (19) (20) (21) (22) .
Several immunologically distinct isozymes of PLC (2, 23) have been purified from bovine brain, and these enzymes exhibit absolute specificity for inositol phospholipid substrates (1, 2) . In the present study, we have microinjected two isozymes of PLC into quiescent NIH 3T3 cells to directly test the growth-promoting and oncogenic potential of these enzymes.
MATERIALS AND METHODS
Cell Culture. NIH 3T3 fibroblast cells were obtained from D. Lowey (National Cancer Institute) and cultured in Dulbecco's modified Eagle's medium with 10% (vol/vol) calf serum, penicillin (100 units/ml), streptomycin (100 ,ug/ml), and L-glutamine (4 mM). The cells (25,000 cells per ml) were applied to glass coverslips in 35-mm plates and allowed to grow until near confluency for 1-2 days.
Enzymes. PLC-I and PLC-II were purified from bovine brain as described (1 respond mitogenically to E2 in vitro, they respond normally with respect to PGR induction. The basallevels of PGR in MIII cells appear higher than the other cell lines, but this is not significant (P > 0.05 for MIII versus MCF-7). MIII, BSK-2, and BSK-3 cells have acquired the ability to form ovarian-independent tumors but the level of EGF-R expression in BSK-2 cells is not substantially different from that in MCF-7 cells. MIII and BSK-3 cells express lower levels of EGF-R when compared with MCF-7 orBSR-2 cells.
Invasive Properties of Cell Lines in Vivo and in Vitro. The gross morphology of MIII and BSK tumors in either the presence or absence of E2 is similar to the parental tumors (Fig. 3) . However, MIII tumors often exhibit considerable invasion into surrounding tissues, leading to occasional intraperitoneal tumor formation. Intraperitoneal tumors occur in both the presence and absence of E2 supplementation. Fig. 3A shows an MIII tumor invading through the peritoneal wall. In contrast, MCF-7 and BSK tumors are frequently encapsulated and show no evidence of local invasion into the peritoneal cavity. Fig. 3B shows a representative MCF-7 tumor growing subcutaneously but no significant invasion into surrounding skin tissue. While BSK cells possess similar chemoinvasive properties as the parental cell line, MIII cells are significantly more invasive across an artificial basement membrane in vitro (Fig. 4) . Thus, under conditions in which 
DISCUSSION
Characterization of the Hormone-Independent but Responsive Phenotype. The E2 dependence of MCF-7 cells for tumor formation in ovariectomized mice is widely reported (6, 14, 16, 17) and may reflect, in part, the routine maintenance of these cells in the presence ofestrogen. The ability of MIII and BSK cells to form E2-responsive tumors in ovariectomized animals clearly indicates that they have progressed to the intermediate stage of hormone-independent but hormoneresponsive growth observed in experimental rodent mammary and prostate cancers (1, 2).
The incidence of MIII tumors in ovariectomized animals reaches the incidence observed in E2-supplemented animals between 12 and 20 passages after establishment in vitro. Thus, further adaptation occurred after their initial development in vivo, perhaps reflecting either the progressive elimination or adaptation of some subpopulations as implied by the observed alterations in the chromosome number range. Since the BSK and MIII cell lines are not clonal in origin, the ovarian-independent but responsive phenotype could reflect the presence of at least two populations of cells, one ovarian dependent and the other independent.
Ovarian-independent and hormone-unresponsive cell lines and tumors are frequently characterized by a loss of ER and elevated EGF-R expression (18, 19) . MIII and BSK-2 cells express similar levels of ER to the parent cell line. EGF-R levels are equivalent in MCF-7 and BSK-2 cells and lower in BSK-3 and MIII cells. The different levels of expression of EGF-R may reflect the presence or absence of estrogenic stimuli, since EGF-R in human breast cancer cells is reported to be increased by treatment with E2 (20) . The PR present in BSK-2 cell culture medium could be providing the estrogenic stimulus responsible for the elevated EGF-R levels relative to MIII and BSK-2 cells (9) . Acquisition of ovarian-independent and hormone-unresponsive growth in some rat mammary tumors occurs without significant loss of ER and PGR expression (21 DNA synthesis is the result of S-phase induction of Goarrested cells and not an artifact of DNA excision repair mechanisms.
Intermediates of phosphoinositol metabolism have been shown (25) to be required for the growth-promoting signal transduction of platelet-derived growth factor and bombesin. Matuoka et al. (25) microinjected a monoclonal antibody specific for phosphatidylinositol-4,5-bisphosphate into the cytoplasm of NIH 3T3 cells that resulted in blocking DNA synthesis induced by platelet-derived growth factor and bombesin but not by fibroblast growth factor, epidermal growth factor, insulin, or serum. Their experimental results suggest that platelet-derived growth factor and bombesin activate membrane receptors that transduce growth-promoting signals through the inositol phospholipid pathway. This is consistent with our microinjection studies of PLC that demonstrate that inositol phospholipid turnover is involved in cellular proliferation. PLC and cellular oncogenes, such as src (15) and crk (17) , contain regions of sequence homology that are likely to serve a common regulatory function in these signal transduction pathways.
The biochemical role of PLC and the activity of G proteins in inositol phospholipid signal transduction remain obscure. Neutralizing monoclonal antibodies specific for PLC and inositol phospholipid intermediates can be utilized to further study the biochemical role of PLC in normal and transformed cells. The ras protein has been shown to be involved in phosphoinositol turnover (26, 27) . In conjunction with the ras-neutralizing monoclonal antibody Y13-259 and various oncogene-transformed NIH 3T3 cells (23) , the exact role of PLC and G proteins in the inositol phospholipid signal transduction pathway can be elucidated with the microinjection assay.
The availability of cloned cDNA for PLC (15, 16) will make it possible to pursue structure-function studies of PLC.
Utilizing site-directed mutagenesis, mutant PLC protein will be expressed in bacterial or eukaryotic expression systems. Enzymatic activity will be determined and their transforming potential will be assessed using the microinjection assay. The present report has established a bioassay for the intracellular mitogenic activity of PLC.
